Biotech Association warns legislation would make VT least friendly state for biotech and life sciences

first_imgIn testimony to the Legislature, New England Biotech Association (NEBA) has warned that a bill under consideration by the Vermont Legislature will create the most restrictive and onerous regulatory environment for biotechnology growth and development in both New England and the nation. The bill, 48/H. 270, would established stricter controls on interactions between the biopharmeceutical industry and health care professionals.      The legislation would eliminate existing protections of trade secrets, create an unneeded new state bureaucracy, and drive away research funding by mandating additional disclosure of expenditures, said NEBA spokeswoman Paula Newton, adding that four other states have rejected similar legislation.”Plain and simple, this legislation will harm Vermont’s biotechnology and life sciences sector and drive jobs away,” Newton said.NEBA serves as the regional policy and public affairs voice for the biotechnology and biopharmaceutical community, representing state biotech associations, companies, academic institutions, and other organizations consisting of more than 800 entities.”Vermont already has one of the strictest pharmaceutical marketing disclosure laws in the country, so the onerous regulatory regime contemplated by the Legislation is wholly unnecessary and should bedefeated,” continued Newton. “Physicians are trusted professionals, and introducing unreasonably broad controls and prohibitions on the interactions between the biopharmaceutical industry and doctors is unwarranted and contrary to health interests of Vermonters who stand to benefit from miracle drugs.”Four other states, including New England states Maine and Rhode Island, have recently rejected marketing restriction legislation far less extreme than the Vermont bill, declaring the measures as bad policy with negative consequences for the life sciences industry and the jobs it produces. An overly restrictive disclosure law recently passed in Massachusetts — less strict than the Vermont proposal — has resulted in a drop in clinical trials and the cancellation of a major medical convention and the associated tourism and tax revenue.NEBA is a non-profit, member-driven organization comprised of state biotech associations, companies, academic institutions, and other organizations with a collective mission to support and grow the biotechnology industry in New England.MONTPELIER, Vt., April 24 /PRNewswire/ –olast_img

Leave a Reply

Your email address will not be published. Required fields are marked *